Key Highlights
- BHVN is trading up 28.34% at $15.08 on October 22, with a market capitalization of about $2.3 billion.
- The prior close was $11.75, so the shares are recovering ground lost after the September partial clinical hold.
- Cash and equivalents were $270.5 million at June 30, and the second-quarter net loss was $137.3 million.
- A licensing deal with SK Biopharmaceuticals carries up to $795 million, including $400 million in near-term cash.
- The Ono Pharmaceutical agreement brought $80 million at signing plus royalties of about 20%.
Why Is Biohaven Stock Surging on October 22?
Biohaven (NYSE:BHVN) is trading up 28.34% at $15.08 on October 22 after the FDA accepted the company's resubmitted new drug application for Vyglxia in spinocerebellar ataxia, a rare inherited neurological disorder. Reports describing the update had the shares up about 29% before the open and above 34% at one point in the morning.
What investors may be missing is that acceptance of a resubmission is a process milestone and not an approval. It means the agency has agreed the filing is complete enough to review again, which restarts a clock that had been uncertain. The prior close was $11.75, so the move lifts the stock back above where it traded before the September setback.
How Large Is the Rebound Compared With the September Selloff?
On September 10 the FDA placed a partial clinical hold on new enrollment in the company's epilepsy trials of opakalim, also known as BHV-7000, and the shares fell about 15% that session. RBC Capital then cut its rating to sector perform and lowered its target to $19 from $23, a data point and not a recommendation.
Today's gain is roughly twice the size of that decline, calculated from the figures above. Biohaven is a clinical-stage company working on neurology, immunology and oncology candidates, so a single regulatory update can move the shares sharply in either direction.
Can Licensing Revenue Offset a $137 Million Quarterly Loss?
Biohaven reported a second-quarter net loss of $137.3 million, or $0.91 per share, on research and development spending of $100.8 million. Cash and equivalents were $270.5 million at June 30. Management did not give financial guidance, though it expects topline results from the RISE3 Phase 2/3 opakalim study and the start of a pivotal IgA nephropathy study in the second half of 2026.
Two deals have since added to the cash picture. On August 26 the company granted SK Biopharmaceuticals a worldwide license to its Kv7 ion channel platform, led by opakalim, with up to $795 million in payments including $400 million in near-term cash ($350 million at closing and $50 million in 2027). Closing depends on antitrust and other reviews.
On October 8 it licensed its IgG degrader portfolio to Ono Pharmaceutical for Japan, South Korea, Taiwan and ASEAN countries, for $80 million at signing, a conditional $20 million milestone and royalties of about 20%. The lead asset, BHV-1300, is in Phase 3 for Graves' disease.
What Comes Next After the Vyglxia Acceptance?
The next checkpoints are the ESMO presentation of Phase 1 data for the FGFR3-directed antibody-drug conjugate BHV-1530 on October 23, the closing of the SK Biopharmaceuticals transaction, and the RISE3 topline readout expected in the second half of the year. The FDA's review of Vyglxia now becomes the central regulatory item, and the status of the epilepsy enrollment hold remains an open question for the opakalim program.






Please wait processing your request...